Significance of Nestin and CD133 as cancer stem cell markers in diffuse glioma and association with p53 expression and IDH status.

IF 1.1 Q4 ONCOLOGY

International journal of clinical and experimental pathology Pub Date : 2024-07-15 eCollection Date: 2024-01-01 DOI:10.62347/YXVS6225

Sivaranjani Selvaraj, Bheemanathi Hanuman Srinivas, Surendra Kumar Verma, Gopalakrishnan Ms

{"title":"Significance of Nestin and CD133 as cancer stem cell markers in diffuse glioma and association with p53 expression and IDH status.","authors":"Sivaranjani Selvaraj, Bheemanathi Hanuman Srinivas, Surendra Kumar Verma, Gopalakrishnan Ms","doi":"10.62347/YXVS6225","DOIUrl":null,"url":null,"abstract":"Background: Recent evidence suggests that the tumor stem cells that are responsible for the pathogenesis of gliomas have similar properties to those of neural stem cells. We have studied two of the most consistently expressed stem cell markers in gliomas, i.e., CD133 and Nestin, and compared them with respect to p53 expression and IDH status.Objectives: To assess the level of expression of Nestin and CD133, and identify a correlation among various grades of diffuse glioma with IDH status and expression of p53.Materials and methods: A cross-sectional retrospective study with 102 subjects for the expression of cancer stem cell markers; CD133 and Nestin and the correlation of their expression with that of p53 and IDH1 status in adult diffuse glioma. The study was conducted in the Departments of Pathology and Neurosurgery. The expression was assessed by immunohistochemistry on formalin-fixed paraffin-embedded sections. The scoring of expression of CD133 and Nestin was adapted from Zhang et al. The scoring for p53 was adopted from Aruna et al. Results: The diffuse gliomas were graded based on WHO into grade II (30.3%), grade III (28.4%), and grade IV (41.3%). Among WHO grade IV, 59.4% were primary, and 40.4% were secondary glioblastomas. 73% of the diffuse gliomas were IDH mutant, and p53 showed an overall expression of 76.4%. The expression of CD133 and Nestin were compared with the increasing grades of diffuse gliomas, which, when plotted on ROC curves, had AUCs of 0.6806 and 0.6119, respectively. Their expression showed a positive correlation with the IDH status of the tumor.Conclusions: Cancer stem cell markers CD133 and Nestin are expressed in diffuse glioma and have a higher expression with increasing WHO grade of malignancy. These cancer stem cell markers have shown significant association with the IDH-1 mutant status of diffuse gliomas. Hence, it can be inferred that diffuse gliomas with a higher expression of CD133 and Nestin have a poorer prognosis. Further, these cancer stem cell markers may be used as therapeutic targets in the future.","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301415/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical and experimental pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/YXVS6225","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recent evidence suggests that the tumor stem cells that are responsible for the pathogenesis of gliomas have similar properties to those of neural stem cells. We have studied two of the most consistently expressed stem cell markers in gliomas, i.e., CD133 and Nestin, and compared them with respect to p53 expression and IDH status.

Objectives: To assess the level of expression of Nestin and CD133, and identify a correlation among various grades of diffuse glioma with IDH status and expression of p53.

Materials and methods: A cross-sectional retrospective study with 102 subjects for the expression of cancer stem cell markers; CD133 and Nestin and the correlation of their expression with that of p53 and IDH1 status in adult diffuse glioma. The study was conducted in the Departments of Pathology and Neurosurgery. The expression was assessed by immunohistochemistry on formalin-fixed paraffin-embedded sections. The scoring of expression of CD133 and Nestin was adapted from Zhang et al. The scoring for p53 was adopted from Aruna et al. Results: The diffuse gliomas were graded based on WHO into grade II (30.3%), grade III (28.4%), and grade IV (41.3%). Among WHO grade IV, 59.4% were primary, and 40.4% were secondary glioblastomas. 73% of the diffuse gliomas were IDH mutant, and p53 showed an overall expression of 76.4%. The expression of CD133 and Nestin were compared with the increasing grades of diffuse gliomas, which, when plotted on ROC curves, had AUCs of 0.6806 and 0.6119, respectively. Their expression showed a positive correlation with the IDH status of the tumor.

Conclusions: Cancer stem cell markers CD133 and Nestin are expressed in diffuse glioma and have a higher expression with increasing WHO grade of malignancy. These cancer stem cell markers have shown significant association with the IDH-1 mutant status of diffuse gliomas. Hence, it can be inferred that diffuse gliomas with a higher expression of CD133 and Nestin have a poorer prognosis. Further, these cancer stem cell markers may be used as therapeutic targets in the future.

查看原文本刊更多论文

弥漫性胶质瘤中作为癌症干细胞标志物的Nestin和CD133的意义以及与p53表达和IDH状态的关系

背景：最近的证据表明，导致胶质瘤发病的肿瘤干细胞具有与神经干细胞相似的特性。我们研究了胶质瘤中两种最常表达的干细胞标志物，即CD133和Nestin，并比较了它们与p53表达和IDH状态的关系：评估 Nestin 和 CD133 的表达水平，并确定弥漫性胶质瘤不同分级与 IDH 状态和 p53 表达的相关性：横断面回顾性研究：对102名受试者进行癌症干细胞标记物CD133和Nestin的表达以及它们的表达与成人弥漫性胶质瘤中p53和IDH1状态的相关性研究。这项研究在病理科和神经外科进行。在福尔马林固定的石蜡包埋切片上用免疫组织化学方法评估其表达。对 CD133 和 Nestin 表达的评分参照了 Zhang 等人的研究；对 p53 的评分参照了 Aruna 等人的研究：弥漫性胶质瘤根据WHO分级为II级（30.3%）、III级（28.4%）和IV级（41.3%）。在WHO IV级中，59.4%为原发性胶质母细胞瘤，40.4%为继发性胶质母细胞瘤。73%的弥漫性胶质瘤为IDH突变，p53的总体表达率为76.4%。将 CD133 和 Nestin 的表达与弥漫性胶质瘤级别的升高进行比较，绘制成 ROC 曲线后，其 AUC 分别为 0.6806 和 0.6119。它们的表达与肿瘤的IDH状态呈正相关：结论：肿瘤干细胞标记物CD133和Nestin在弥漫性胶质瘤中均有表达，且随着WHO恶性程度的升高，其表达量也随之升高。这些癌症干细胞标记物与弥漫性胶质瘤的IDH-1突变状态有显著关联。因此，可以推断CD133和Nestin表达量较高的弥漫性胶质瘤预后较差。此外，这些癌症干细胞标志物将来可能被用作治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical and experimental pathology ONCOLOGY-PATHOLOGY

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) is a peer reviewed, open access online journal. It was founded in 2008 by an international group of academic pathologists and scientists who are devoted to the scientific exploration of human disease and the rapid dissemination of original data. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal.